PMID- 31002948
OWN - NLM
STAT- MEDLINE
DCOM- 20200521
LR  - 20200521
IS  - 1873-5835 (Electronic)
IS  - 0145-2126 (Linking)
VI  - 81
DP  - 2019 Jun
TI  - Relationship between CD34/CD38 and side population (SP) defined leukemia stem 
      cell compartments in acute myeloid leukemia.
PG  - 27-34
LID - S0145-2126(19)30068-2 [pii]
LID - 10.1016/j.leukres.2019.04.004 [doi]
AB  - Leukemic stem cells (LSCs), defined by CD34/CD38 expression, are believed to be 
      essential for leukemia initiation and therapy resistance in acute myeloid 
      leukemia. In addition, the side population (SP), characterized by high Hoechst 
      33342 efflux, reflecting therapy resistance, has leukemia initiating ability. The 
      purpose of this study is, in both CD34-positive and CD34-negative AML, to 
      integrate both types of LSC compartment into a new more restricted definition. 
      Different CD34/CD38/SP defined putative LSC and normal hematopoietic 
      compartments, with neoplastic or normal nature, respectively, were thus 
      identified after cell sorting, and confirmed by FISH/PCR. Stem cell activity was 
      assessed in the long-term liquid culture stem cell assay. SP fractions harbored 
      the strongest functional stem cell activity in both normal and neoplastic cells 
      in both CD34-positive and CD34-negative AML. Overall, inclusion of SP fraction 
      decreased the size of the putative CD34/CD38 defined LSC compartment by a factor 
      >500. For example, for the important CD34+CD38- LSC compartment, the median 
      SP/CD34+CD38- frequency was 5.1 per million WBC (CD34-positive AML), and median 
      SP/CD34-CD38+ frequency (CD34-negative AML) was 1796 per million WBC. Improved 
      detection of LSC may enable identification of therapy resistant clones, and 
      thereby identification of novel LSC specific, HSC sparing, therapies.
CI  - Copyright (c) 2019 Elsevier Ltd. All rights reserved.
FAU - Moshaver, Bijan
AU  - Moshaver B
AD  - Department of Hematology, Cancer Center Amsterdam, VU University Medical Center, 
      1081HV Amsterdam, the Netherlands.
FAU - Wouters, Rolf F
AU  - Wouters RF
AD  - Department of Hematology, Cancer Center Amsterdam, VU University Medical Center, 
      1081HV Amsterdam, the Netherlands; Department of Pediatric Oncology, Cancer 
      Center Amsterdam, VU University Medical Center, 1081HV Amsterdam, the 
      Netherlands.
FAU - Kelder, Angele
AU  - Kelder A
AD  - Department of Hematology, Cancer Center Amsterdam, VU University Medical Center, 
      1081HV Amsterdam, the Netherlands.
FAU - Ossenkoppele, Gert J
AU  - Ossenkoppele GJ
AD  - Department of Hematology, Cancer Center Amsterdam, VU University Medical Center, 
      1081HV Amsterdam, the Netherlands.
FAU - Westra, Guus A H
AU  - Westra GAH
AD  - Department of Hematology, Cancer Center Amsterdam, VU University Medical Center, 
      1081HV Amsterdam, the Netherlands.
FAU - Kwidama, Zinia
AU  - Kwidama Z
AD  - Department of Hematology, Cancer Center Amsterdam, VU University Medical Center, 
      1081HV Amsterdam, the Netherlands; Department of Pediatric Oncology, Cancer 
      Center Amsterdam, VU University Medical Center, 1081HV Amsterdam, the 
      Netherlands.
FAU - Rutten, Arjo R
AU  - Rutten AR
AD  - Department of Hematology, Cancer Center Amsterdam, VU University Medical Center, 
      1081HV Amsterdam, the Netherlands.
FAU - Kaspers, Gert J L
AU  - Kaspers GJL
AD  - Department of Pediatric Oncology, Cancer Center Amsterdam, VU University Medical 
      Center, 1081HV Amsterdam, the Netherlands.
FAU - Zweegman, Sonja
AU  - Zweegman S
AD  - Department of Hematology, Cancer Center Amsterdam, VU University Medical Center, 
      1081HV Amsterdam, the Netherlands.
FAU - Cloos, Jacqueline
AU  - Cloos J
AD  - Department of Hematology, Cancer Center Amsterdam, VU University Medical Center, 
      1081HV Amsterdam, the Netherlands; Department of Pediatric Oncology, Cancer 
      Center Amsterdam, VU University Medical Center, 1081HV Amsterdam, the 
      Netherlands.
FAU - Schuurhuis, Gerrit J
AU  - Schuurhuis GJ
AD  - Department of Hematology, Cancer Center Amsterdam, VU University Medical Center, 
      1081HV Amsterdam, the Netherlands. Electronic address: gj.schuurhuis@vumc.nl.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190409
PL  - England
TA  - Leuk Res
JT  - Leukemia research
JID - 7706787
RN  - 0 (Antigens, CD34)
RN  - EC 3.2.2.6 (ADP-ribosyl Cyclase 1)
SB  - IM
MH  - ADP-ribosyl Cyclase 1/*metabolism
MH  - Antigens, CD34/*metabolism
MH  - Cells, Cultured
MH  - Hematopoietic Stem Cells/metabolism/*pathology
MH  - Humans
MH  - Immunophenotyping
MH  - Leukemia, Myeloid, Acute/metabolism/*pathology
MH  - Neoplastic Stem Cells/metabolism/*pathology
MH  - Side-Population Cells/metabolism/*pathology
OTO - NOTNLM
OT  - AML
OT  - CD34+CD38-
OT  - Flowcytometry
OT  - Leukemia stem cell
OT  - Side population (SP)
EDAT- 2019/04/20 06:00
MHDA- 2020/05/22 06:00
CRDT- 2019/04/20 06:00
PHST- 2019/01/14 00:00 [received]
PHST- 2019/04/04 00:00 [revised]
PHST- 2019/04/08 00:00 [accepted]
PHST- 2019/04/20 06:00 [pubmed]
PHST- 2020/05/22 06:00 [medline]
PHST- 2019/04/20 06:00 [entrez]
AID - S0145-2126(19)30068-2 [pii]
AID - 10.1016/j.leukres.2019.04.004 [doi]
PST - ppublish
SO  - Leuk Res. 2019 Jun;81:27-34. doi: 10.1016/j.leukres.2019.04.004. Epub 2019 Apr 9.